Last reviewed · How we verify

Hyperhidrosis of palms — Treatment Landscape & Competitive Intelligence

Hyperhidrosis of palms (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Hyperhidrosis of palms, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Ditropan Xl OXYBUTYNIN Hisamitsu Pharmaceutical Co., Inc. Cholinergic Muscarinic Antagonist Muscarinic acetylcholine receptor M3 1975-01-01
Oxytrol Oxytrol Jewish General Hospital Cytochrome P450 2C19, 5-hydroxytryptamine receptor 2B, D(3) dopamine receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Hisamitsu Pharmaceutical Co., Inc. · 1 drug in Hyperhidrosis of palms
  2. Jewish General Hospital · 1 drug in Hyperhidrosis of palms

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Hyperhidrosis of palms:

Cite this brief

Drug Landscape (2026). Hyperhidrosis of palms — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/hyperhidrosis-of-palms. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing